LOS ANGELES, May 24, 2005 (PRIMEZONE) -- BiomedDiscoveries.com, http://www.BiomedDiscoveries.com, the online source for exclusive investor information in the biotechnology sector, has announced the availability of an online interview with Dr. Steven Warsof, Associate Professor and Director of Prenatal Diagnosis at the Center for Advanced Fetal Therapy at the Eastern Virginia Medical School, a leading healthcare facility in Norfolk, Virginia. Dr. Warsof will discuss a collaborative research program with Xenomics Inc. (OTCBB:XNOM), which is developing proprietary next-generation technology to create a new class of highly accurate, but completely non-invasive method of conducing medical DNA tests to diagnose diseases and genetic abnormalities.
Xenomics and Eastern Virginia Medical School (EVMS) have recently executed an agreement to begin human clinical trials that will investigate the ability of Xenomics' Transrenal-DNA (Tr-DNA) to detect a number of fetal genetic problems through analysis of urine samples of pregnant women. The clinical study is subject to review and approval by the institutional review board of EVMS.
In the interview, Dr. Warsof discussed the current prenatal diagnostics tests and their dangers. "Diagnostic testing such as amniocentesis does have a risk to it," he said. "Although we consider the procedure safe, there is a risk and usually amniocentesis has a one-half to one percent loss rate after the procedure." By contrast, Xenomics tests present no risk to mother or child. They require only a safe, non-invasive urine sample. Preliminary work showed an ability to detect fetal DNA as early as seven weeks into pregnancy, instead of the 15- to 22-week window commonly used in amniocentesis. Dr. Warsof continues, "In many ways this is the Holy Grail of prenatal diagnosis, in so much as it is non-invasive, has no risk to the patient, it can be done very early in the pregnancy. So it is very likely this is the test that can be offered to every pregnant woman in the United States".
The streaming audio interview can be accessed at http://www.BiomedDiscoveries.com. Registration to listen to the interview is free.
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Statements made on BiomedDiscoveries.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by BiomedDiscoveries.com. Compensation and Other Disclosures BiomedDiscoveries.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from Xenomics of $10,000 per month through January 2006 and thereafter for so long as Trilogy is retained to provide investor relations services.
The Company issued Trilogy warrants to purchase 1,000,000 shares of Common Stock of the Company at an exercise price of $2.95 per share (the ``Warrants''). The Warrants issued to Trilogy are exercisable upon issuance and expire on January 10, 2008. In the event the Company proposes to register any of its Common Stock under the Securities Act of 1933 for sale in connection with a public offering of Common Stock, the Company will give written notice to Trilogy and will include in such registration statement any of the shares of Common Stock underlying the Warrants which Trilogy may request be included. The offer and sale of these securities was made in reliance on Section 4(2) of the Securities Act of 1933, as amended. The offer and sale of the Warrants did not involve a public offering.